Hikma To Pay $2.7B For Boehringer US Unit
Hikma Pharmaceuticals PLC on Tuesday said that it has struck a $2.65 billion cash-and-stock deal to buy a specialty generic drug business from Boehringer Ingelheim Pharmaceuticals Inc., again expanding its presence...To view the full article, register now.
Already a subscriber? Click here to view full article